About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Dana-Farber Cancer Institute
https://www.dana-farber.org/
2023-2024 EMBRACE MBC Virtual Forum Series
ASCO® GU 2024
ASCO® 2023
COVID-19
Leukemia
Lymphoma
Myeloma
MDS and MPN
Breast
Lung
Gynecologic
Genitourinary
Gastrointestinal
Colorectal
Basic Science
Supportive and Palliative Care
CNS
Skin
Head and Neck
Business
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
W
Kidney Cancer Highlights From ESMO 2023
By
Dana-Farber Cancer Institute
FEATURING
Wenxin Xu
,
Toni Choueiri
By
Dana-Farber Cancer Institute
FEATURING
Wenxin Xu
,
Toni Choueiri
164 views
December 11, 2023
0 Comments
Login to view comments.
Click here to Login
Featured Video
13:04
Winship Cancer Institute - Emory University
Treatment-Related Quality of Life in MF
Feat.
A. Hunter
Featured Video
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
Genitourinary
28:34
Dana-Farber Cancer Institute
Prostate Cancer Highlights From ESMO 2023
Feat.
M. Serzan,
M. Taplin
20:40
Dana-Farber Cancer Institute
Kidney Cancer Highlights From ESMO 2023
Feat.
W. Xu,
T. Choueiri
02:33
Dana-Farber Cancer Institute
ESMO 2023 Summary: "Refining Risk Stratification in Patients Un…
Feat.
P. Ravi
01:53
ecancer
ESMO 2023 Insights: "Results From Phase 2 LITESPARK-003 Study -…
Feat.
T. Choueiri
02:23
ecancer
ESMO 2023 Insights: "Comparing Belzutifan With Everolimus in Pr…
Feat.
T. Choueiri
25:33
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute Prostate Cancer Updates From ASCO GU 20…
Feat.
J. Berchuck,
A. Choudhury
04:50
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute Testicular Cancer Updates From ASCO GU …
Feat.
A. Tewari
20:18
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute Kidney Cancer Updates From ASCO GU 2023
Feat.
W. Xu,
T. Choueiri
19:48
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute Bladder Cancer Updates From ASCO GU 2023
Feat.
C. Mantia,
J. Bellmunt
15:35
Dana-Farber Cancer Institute
Updates on the Management of Non-Clear Cell RCC
Feat.
B. McGregor
14:36
OncoAlert
RCC Updates: Perioperative Treatment, Metastatic ccRCC, and Non-Clea…
Feat.
T. Choueiri
14:01
ASCO GU 2023 Conference Coverage
ASCO GU 2023 Active Surveillance for Favorable Intermediate-Risk Pro…
Feat.
A. D'Amico
51
Dana-Farber Cancer Institute
Lecture Summary - CARD Trial: Safety and Efficacy of Cabazitaxel in …
Feat.
A. Choudhury
09:06
Dana-Farber Cancer Institute
CARD Trial: Safety and Efficacy of Cabazitaxel in mCRPC & Age Su…
Feat.
A. Choudhury
03:13
Dana-Farber Cancer Institute
Outcomes of1L Ipi-Nivo & Subsequent Therapy in mRCC: Results Fro…
Feat.
A. Schmidt
25:49
Dana-Farber Cancer Institute
Beyond "The Big Three" Lynch Syndrome-Linked Cancers: What…
Feat.
M. Yurgelun
13:19
Dana-Farber Cancer Institute
2020 ESMO IPATential150 Trial Data on mCRPC: Does Ipatasertib Combin…
Feat.
C. Sweeney
26:17
Dana-Farber Cancer Institute
Current and Emerging Agents to Treat Advanced Bladder Cancer
Feat.
G. Sonpavde
10:29
Dana-Farber Cancer Institute
Study of Atezolizumab and Bevacizumab in Variant Histology RCC: Data…
Feat.
B. McGregor
08:37
Dana-Farber Cancer Institute
DFCI's ASCO 2019 Update: Review of FDA's Approval of the F…
Feat.
G. Sonpavde
16:32
Dana-Farber Cancer Institute
DFCI's ASCO 2019 Update on Metastatic Urothelial Carcinoma: Ana…
Feat.
G. Sonpavde
